For laboratory research use only — not for human consumption
For laboratory research use only — not for human consumption
Comparison
A neutral, structural comparison of BPC-157 and Retatrutide as research compounds — written for researchers evaluating the two. It describes structure and research context only; it makes no human-use, dosing, or therapeutic claim. Both are supplied for in-vitro laboratory research use only.
| BPC-157 | Retatrutide | |
|---|---|---|
| Class | Synthetic pentadecapeptide | Triple-agonist peptide (GLP-1 / GIP / glucagon) |
| Research area | Peptide & tissue-signalling research | Metabolic & receptor-signalling research |
| CAS number | 137525-51-0 | 2381089-83-2 |
| Molecular formula | C62H98N16O22 | C221H342N46O68 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | — |
| HPLC purity | 98.67% | 99.66% |
BPC-157 is a synthetic pentadecapeptide (a 15-amino-acid sequence) widely used as a reference compound in laboratory peptide research. It is one of the most frequently studied research peptides and appears often alongside TB-500 in comparative literature.
Retatrutide is a synthetic triple-agonist peptide investigated in laboratory research into metabolic and receptor-signalling pathways. It is studied for its simultaneous activity across the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor systems — the reason it appears frequently in comparative metabolic-research literature alongside single-agonist (GLP-1) and dual-agonist (GLP-1/GIP) reference peptides.
Both compounds are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. This comparison is structural and contextual and does not constitute advice on use.
